Cash, cash equivalents and restricted cash as of December 31, 2024 was $214.3 million and is expected to support planned operations, including completion of planned Phase 3 AURORA trial for Descartes-08 in MG, into mid-2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces employment inducement grant
- Is RNAC a Buy, Before Earnings?
- Cartesian Therapeutics Advances Descartes-08 in Clinical Trials
- Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership
- Cartesian Therapeutics announces new employment inducement grants